Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation.

Meyers, Christina A.; Weitzner, Michael A.; Byrne, Kevin; Valentine, Alan D.; Champlin, Richard E.; Przepiorka, Donna

doi:10.1200/jco.1994.12.4.820

Cited by 126 publications

(119 citation statements)

References 18 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…These results are notable because these problems remain largely underdiagnosed, 41,55,56 and most would be expected to be exacerbated rather than diminished with the beginning of aggressive high-dose therapy and transplant regimens. 27,28,33 The prevalence rates found in the present investigation are even higher than those that emerged in our earlier pilot study of myeloma patients at a similar point in treatment; 24 taken together, these studies demonstrate that early psychosocial screening is feasible in a busy treatment center and that supportive care needs are extensive. On the SF-12, for example, 59% of patients in the current study exceeded cutoffs (1 s.d.)…”

Section: Discussioncontrasting

confidence: 51%

“…[26][27][28][29] Rates of distress have been similarly elevated among more heterogeneous samples of patients assessed prior to receiving either autologous, allogeneic, or matched unrelated donor transplants. [30][31][32][33] Many patients also appear to experience compromised physical or functional status prior to autologous transplantation, although here too information is limited. 28,34,35 Most studies that evaluated patients prior to autologous PBSCT have relied on small sample sizes and, as noted, individuals with multiple myeloma were rarely included, in part due to exclusion of older patients from transplant regimens.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation

Sherman

Simonton

Latif

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Stem cell transplantation has assumed a prominent place in the treatment of multiple myeloma, but relative to patients with other malignancies there is surprisingly little information about the adjustment difficulties and qualityof-life changes that these patients experience. This study examined psychosocial and functional deficits among myeloma patients assessed at a uniform period during their initial diagnostic evaluation, prior to beginning protocols at a transplant center. Validated self-report measures and clinician rating scales were used to assess 213 patients. Outcomes evaluated included emotional distress (Hospital Anxiety and Depression Scale, Brief Symptom Inventory), depression (Hamilton Depression Rating Scale), physical functioning, pain, and energy (SF-12). A significant proportion of patients experienced compromised psychosocial and physical functioning. Roughly one-third reported clinically elevated levels of distress, anxiety, and depression. In all, 59% scored below age-adjusted norms for daily physical functioning, 58% reported at least moderate levels of pain, and over 80% noted at least moderate fatigue. Clinical and demographic correlates of these outcomes were examined. These findings are among the first to characterize quality-of-life outcomes among myeloma patients in the transplant setting, and indicate that many patients experience considerable supportive care needs even prior to beginning aggressive regimens. Results highlight the importance of early screening. Bone Marrow Transplantation (2004) 33, 955-962.

show abstract

Section: Discussioncontrasting

confidence: 51%

mentioning

confidence: 99%

Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation

Sherman

Simonton

Latif

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…26,39,40 The prospective design shows a slight decline in anxiety in the SCT group and relatively stable levels (ASCT group) during hospitalization and follow-up, and an increase in depression during hospitalization before it consistently declined in both groups. This pattern of change was in line with two prospective studies employing the State Trait Anxiety Inventory (STAI) and the Zung Depression Inventory, 41 and the POMS, 6 but contradicted slightly with other studies reporting minor changes in psychological distress during follow-up assessed by the POMS 5 and Beck's Depression Inventory (BDI). 4 The level of psychological distress in the transplant patients was generally lower in this report compared with other studies employing the HADS scale.…”

Section: Discussionmentioning

confidence: 49%

“…The multivariate approach in this subgroup of patients showed that higher baseline scores were the strongest predictive factors for more anxiety and depression at subsequent assessments, as well as for anxiety cases after 1 year, as reported by other. 23,41 Treatment with ASCT was associated with more anxiety after 1 year. A less favourable outcome in the ASCT group than in the SCT groups, is in line with our previous report of health-related quality of life.…”

Section: Discussionmentioning

confidence: 99%

The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation

Hjermstad

Loge

Evensen³

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Psychological distress is frequently reported in transplant survivors. We prospectively assessed anxiety and depression before transplant, in the isolation period and during a follow-up period of 1 year. The Hospital Anxiety and Depression Scale (HADS) was administered to 131 cancer patients treated with high-dose chemotherapy followed by allogeneic (SCT) or autologous (ASCT) stem cell transplantation, and a concurrent group of 123 lymphoma patients receiving standard chemotherapy (CT) who served as a reference group. Relatively low levels of anxiety and depression were found. The level of anxiety slightly declined from baseline during follow-up (mean scores SCT: from 5.3 to 3.6, CT: from 6.0 to 4.2) or remained fairly stable (ASCT: from 5.4 to 4.8). The level of depression peaked when the transplant patients were in protective isolation or shortly thereafter (SCT: 6.1, ASCT: 6.4), but stabilized at baseline levels after 4 months. The highest level of depression in the CT group was reported 4 months after start of chemotherapy (3.4). Elevated levels of anxiety and depression at baseline predicted more anxiety and depression at the later assessments (P values Ͻ0.0001). The ASCT group had higher levels of anxiety after 1 year (mean 4.8) than those found in the other two groups (SCT: 3.6, CT: 4.2), although they were not statistically significant. This study revealed lower than expected levels of anxiety and depression after intensive chemotherapy followed by SCT or ASCT. There was a decline in psychological distress during the 1-year follow-up period. Keywords: anxiety; depression; HADS; high-dose chemotherapy; prospective study Allogeneic (SCT) and autologous (ASCT) stem cell transplantation subsequent to high-dose chemotherapy (HDC) produces significant physical morbidity. 1,2 Most patients who undergo high-dose chemotherapy are young, and with increasing numbers of long-term survivors, prospective Correspondence: MJ Hjermstad, Department of Oncology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway Received 18 December 1998; accepted 15 July 1999 data on the prevalence and severity of psychological morbidity are important. In order to identify patients with symptoms of anxiety and depression in the early stages of disease and treatment, who might be at risk of psychological maladjustment after such intensive treatment, it is important to raise the awareness of signs of psychological distress in clinical oncology. A routine-based incorporation of assessment of anxiety and depression might be helpful.Previous studies which have used questionnaires such as the Profile of Moods State (POMS) or the Brief Symptom Inventory (BSI) for the evaluation of anxiety and depression, have shown that psychological distress is frequently reported by SCT and ASCT patients. The percentages of patients with these problems vary from 14% to 41%, depending on the study design, types of measures, and time of assessment relative to diagnoses and treatment. [3][4][5][6][7][8][9] When data from transplant patients ha...

show abstract

“…They reported memory deficits and reduced information-processing speed in particular. Meyers et al 33 reported signs of mild cognitive deficits in 20% of their subjects before HSCT. Andrykowski et al 34 reported similar findings.…”

Section: Introductionmentioning

confidence: 99%

Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic stem cell transplantation

Poppelreuter¹,

Weis²,

Mumm³

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation.

Cited by 126 publications

References 18 publications

Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation

Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation

The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation

Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic stem cell transplantation

Contact Info

Product

Resources

About